BRIJ Medical Seals Premier Deal for Advanced Hypoallergenic Wound Care

SAN DIEGO, CA – July 30, 2026 – In a move that signals a significant shift in the post-operative care landscape, medical device firm BRIJ Medical, Inc. has secured a coveted Breakthrough Technology designation from Premier, Inc. for its BRIJ-SEAL™ Advanced Wound Sealant. Effective August 1, 2026, this agreement provides BRIJ Medical with a direct channel to Premier's enormous network of healthcare providers, potentially reshaping how surgical incisions are managed across North America.

The deal allows members of Premier's Group Purchasing Organization (GPO) to purchase BRIJ-SEAL™ under special, pre-negotiated terms. This isn't just a simple supply contract; it's a powerful endorsement that places an innovative technology into the hands of thousands of surgeons and hospitals, backed by one of the most influential entities in the healthcare supply chain.

The Strategic Gateway: Unpacking the Premier Designation

For any medical device company, gaining traction in the fragmented U.S. healthcare market is a monumental challenge. This is where the strategic power of a GPO like Premier, Inc. becomes clear. Premier is not merely a purchasing group; it is a healthcare improvement giant that unites over 4,250 hospitals and 365,000 other providers, leveraging a combined purchasing volume that exceeds $87 billion. Securing a contract with them is a market-access game-changer.

Premier’s Breakthrough Technology designation is awarded to innovations that demonstrate a major advantage in patient safety, clinical outcomes, or operational efficiency. It's crucial to distinguish this from the FDA's 'Breakthrough Device' designation, which is a regulatory pathway to expedite review. Premier's award is a commercial one, a signal to its vast member base that a product has been vetted by sourcing committees of healthcare experts and deemed worthy of accelerated adoption. This endorsement effectively cuts through the noise of a crowded market, providing a level of credibility that can take years to build independently.

By awarding this designation to BRIJ-SEAL™, Premier's sourcing committees have validated the product's potential to bridge a gap in care and improve the quality of post-surgical healing. For BRIJ Medical, this translates into streamlined market access and a significant competitive advantage.

A New Standard in Sealing: The Hypoallergenic Advantage

At the heart of this deal is the technology itself. BRIJ-SEAL™ is an advanced wound sealant designed to provide a protective barrier over surgical incisions. But its key innovation lies in what it lacks: cyanoacrylates. For decades, cyanoacrylate-based adhesives—a form of medical-grade superglue—have been a mainstay in wound closure. While effective, they carry a known risk of causing allergic contact dermatitis, a red flag for patient safety and comfort.

BRIJ Medical has engineered a solution with its proprietary hypoallergenic adhesive technology. This is the same adhesive platform used in the company's Brijjit® devices, which has demonstrated no reported allergic reactions across six clinical studies. This focus on a hypoallergenic alternative directly addresses a persistent clinical need, offering a safer option for a growing population of patients with skin sensitivities.

Beyond its gentle chemistry, BRIJ-SEAL™ boasts features that align with modern surgical demands. It provides a sterile, waterproof, and breathable barrier designed to protect an incision from bacteria for up to 14 days. This extended protection can reduce the risk of surgical site infections (SSIs), a major source of patient morbidity and increased healthcare costs, while its flexibility allows for patient comfort throughout the healing process.

"Driven by customer feedback, we developed a simpler solution that provides a strong bacterial barrier, minimizes the risk of adhesive-related skin reactions, and can be applied quickly and efficiently," said Tim Gleeson, Chief Executive Officer of BRIJ Medical, in a statement. His comments underscore a development process centered on solving real-world clinical problems.

Building a Comprehensive Incision Management Platform

The designation for BRIJ-SEAL™ is the capstone of a broader strategy for BRIJ Medical. The sealant joins the company’s other core products, the Brijjit® BP-100 and BP-75 Force Modulating Tissue Bridges, which already hold Premier Breakthrough Technology designations. With this trifecta, the San Diego-based firm can now offer a complete, integrated incision management platform through the Premier contract.

This portfolio approach is a sophisticated business play. Brijjit® is an active tension offloading device clinically shown to reduce incision tension, a primary cause of wound complications and excessive scarring. Clinical data from breast studies has demonstrated its ability to reduce wound breakdown by a staggering 90% and minimize scar area by 38%. By pairing this tension-reducing technology with the protective, hypoallergenic barrier of BRIJ-SEAL™, surgeons gain a comprehensive toolkit to optimize healing from the moment of closure through recovery.

"Adding BRIJ-SEAL to our Premier agreement represents more than a product expansion—it reflects our broader vision of giving surgeons optionality through a complete portfolio of innovative technologies that improve healing while simplifying care," Gleeson added. This vision transforms the company from a seller of individual products into a partner in achieving superior surgical outcomes.

From Boardroom to Bedside: The Tangible Impact on Care

The implications of this agreement extend from the hospital purchasing department directly to the patient's bedside. For Premier member facilities, the pre-negotiated contract simplifies procurement, ensures access to vetted technology, and offers a standardized solution that can enhance operational efficiency. A product that reduces the risk of complications like SSIs or allergic reactions can lower downstream costs associated with revision surgeries and extended hospital stays.

For patients, the benefits are even more direct. The availability of a hypoallergenic sealant means less worry about painful skin reactions. The robust 14-day bacterial barrier provides peace of mind and tangible protection against infection. When used as part of BRIJ Medical’s complete platform, patients stand to benefit from faster, more comfortable healing with better cosmetic results—a critical component of patient satisfaction in both reconstructive and elective surgeries.

With all three of its flagship products now carrying Premier's seal of approval, BRIJ Medical has successfully navigated the complex healthcare market to deliver its full suite of innovations on a national scale. This strategic alignment positions BRIJ Medical not just as a product innovator, but as a key architect in the future of post-surgical recovery.